A pooled analysis of treatment and prognosis of hepatic angiosarcomain adults

Background： Hepatic angiosarcoma is a rare malignant vascular tumor presenting unique treatment challenges.The aim of the present study was to determine the treatment and prognosis of this entity.Data sources： A systematic literature search was conducted using PubMed, Embase and Chinese BiomedicalLiterature database, to identify articles published from January 1980 to July 2017. Search termswere “hepatic angiosarcoma” and “liver angiosarcoma”. Additional articles were retrieved through manualsearch of bibliographies of the relevant articles. Pooled individual data concerning the prognosis followingvarious therapeutic modalities were analyzed.

Long-term outcomes of combined hepatocellular-cholangiocarcinoma after hepatectomy or liver transplantation: A systematic review and meta-analysis

Background: Combined hepatocellular-cholangiocarcinoma(cHCC-CC) is a rare primary liver malignancy. We conducted a systematic review and meta-analysis to assess the evidence available on the long-term outcomes of cHCC-CC patients after either hepatectomy or liver transplantation(LT). Data Sources: Relevant studies published between January 2000 and January 2018 were identified by searching Pub Med and Embase and reviewed systematically. Data were pooled using a random-effects model. Results: A total of 42 observational studies involving 1691 patients(1390 for partial hepatectomy and 301 for LT) were included in the analysis. The median tumor recurrence and 5-year overall survival(OS) rates were 65%(range 38%–100%) and 29%(range 0–63%) after hepatectomy versus 54%(range 14%–93%) and 41%(range 16%–73%) after LT, respectively. Meta-analysis found no significant difference in OS and tumor recurrence between LT and hepatectomy groups. Conclusion: Hepatectomy rather than LT should be considered as the prior treatment option for cHCC-CC.

Survival after repeat hepatectomy for recurrent colorectal liver metastasis: A review and meta-analysis of prognostic factors

Background:Frequent recurrent hepatic metastasis after hepatic metastasectomy is a major obstacle in the treatment of colorectal liver metastasis(CRLM).We performed the present systematic review to evaluate the short-and long-term outcomes after repeat hepatectomy for recurrent CRLM and determine factors associated with survival in these patients.Data sources:An electronic search of PubMed database was undertaken to identify all relevant peerreviewed papers published in English between January 20 0 0 and July 2018.Hazard ratios(HR)with 95%confidence interval(95%CI)were calculated for prognostic factors of overall survival(OS).Results:The search yielded 34 studies comprising 3039 patients,with a median overall morbidity of 23%(range 8%–71%),mortality of 0(range 0–6%),and 5-year OS of 42%(range 17%–73%).Pooled analysis showed that primary T3/T4 stage tumor(HR=1.94;95%CI:1.04–3.63),multiple tumors(HR=1.49;95%CI:1.10–2.01),largest liver lesion≥5 cm(HR=1.89;95%CI:1.11–3.23)and positive surgical margin(HR=1.80;95%CI:1.09–2.97)at initial hepatectomy,and high serum level of carcinoembryonic antigen(HR=1.87;95%CI:1.27–2.74),disease-free interval≤12 months(HR=1.34;95%CI:1.10–1.62),multiple tumors(HR=1.64;95%CI:1.32–2.02),largest liver lesion≥5 cm(HR=1.85;95%CI:1.34–2.56),positive surgical margin(HR=2.25;95%CI:1.39–3.65),presence of bilobar disease(HR=1.62;95%CI:1.19–2.20),and extrahepatic metastases(HR=1.60;95%CI:1.23–2.09)at repeat hepatectomy were significantly associated with poor OS.

Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease

Inflammatory bowel disease(IBD) is a chronic relapsing disease in gastrointestinal tract. Conventional medications lack the efficacy to offer complete remission in IBD therapy,and usually associate with serious side effects. Recent studies indicated that nanoparticle-based nanotherapeutics may offer precise and safe alternative to conventional medications via enhanced targeting,sustained drug release,and decreased adverse effects. Here,we reviewed orally cell-specific nanotherapeutics developed in recent years. In addition,the various obstacles for oral drug delivery are also reviewed in this manuscript. Orally administrated cell-specific nanotherapeutics is expected to become a novel therapeutic approach for IBD treatment.